Cargando…

Screening of Fabry disease in patients with chronic kidney disease in Japan

BACKGROUND: Fabry disease (FD), an X-linked lysosomal storage disorder caused by a deficiency in alfa-galactosidase A (α-Gal A) activity due to mutations in the GLA gene, has a prevalence of 0–1.69% in patients undergoing haemodialysis; however, its prevalence in patients with chronic kidney disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagata, Akiko, Nasu, Makoto, Kaida, Yusuke, Nakayama, Yosuke, Kurokawa, Yuka, Nakamura, Nao, Shibata, Ryo, Hazama, Takuma, Tsukimura, Takahiro, Togawa, Tadayasu, Saito, Seiji, Sakuraba, Hitoshi, Fukami, Kei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719579/ https://www.ncbi.nlm.nih.gov/pubmed/34282462 http://dx.doi.org/10.1093/ndt/gfaa324

Ejemplares similares

Erratum to: Screening of Fabry disease in patients with chronic kidney disease in Japan
por: Nagata, Akiko, et al.
Publicado: (2021)

Effectiveness of immunosuppressive therapy for nephrotic syndrome in a patient with late-onset Fabry disease: a case report and literature review
por: Fujisawa, Hironobu, et al.
Publicado: (2019)

Genetically Modified Cell Transplantation Through Macroencapsulated Spheroids with Scaffolds to Treat Fabry Disease
por: Kami, Daisuke, et al.
Publicado: (2021)

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease
por: Tsukimura, Takahiro, et al.
Publicado: (2014)

Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Fabry disease in a Japanese population-molecular and biochemical characteristics
por: Sakuraba, Hitoshi, et al.
Publicado: (2018)

Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease
por: Shiga, Tomoko, et al.
Publicado: (2021)

Cell Transplantation Combined with Recombinant Collagen Peptides for the Treatment of Fabry Disease
por: Kami, Daisuke, et al.
Publicado: (2020)

Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy
por: Kubota, Takao, et al.
Publicado: (2022)

Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
por: Tsukimura, Takahiro, et al.
Publicado: (2021)

Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy
por: Tsukimura, Takahiro, et al.
Publicado: (2020)

Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis of Fabry disease
por: Sakuraba, Hitoshi, et al.
Publicado: (2015)

Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations
por: Moriyama, Tomofumi, et al.
Publicado: (2020)

Surface plasmon resonance analysis of complex formation of therapeutic recombinant lysosomal enzymes with domain 9 of human cation-independent mannose 6-phosphate receptor
por: Kanzaki, Minori, et al.
Publicado: (2020)

A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry
por: Nasu, Makoto, et al.
Publicado: (2022)

l‐carnitine supplementation vs cycle ergometer exercise for physical activity and muscle status in hemodialysis patients: A randomized clinical trial
por: Yano, Junko, et al.
Publicado: (2020)

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy
por: Nakano, Sachie, et al.
Publicado: (2015)

In Vivo Delivery of Therapeutic Molecules by Transplantation of Genome-Edited Induced Pluripotent Stem Cells
por: Nakajima, Ittetsu, et al.
Publicado: (2023)

Lyso-GM2 Ganglioside: A Possible Biomarker of Tay-Sachs Disease and Sandhoff Disease
por: Kodama, Takashi, et al.
Publicado: (2011)

Development of a Highly Sensitive Immuno-PCR Assay for the Measurement of α-Galactosidase A Protein Levels in Serum and Plasma
por: Nakano, Sachie, et al.
Publicado: (2013)

The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient
por: Taguchi, Kensei, et al.
Publicado: (2017)

Effects of Reducing L-Carnitine Supplementation on Carnitine Kinetics and Cardiac Function in Hemodialysis Patients: A Multicenter, Single-Blind, Placebo-Controlled, Randomized Clinical Trial
por: Sugiyama, Miki, et al.
Publicado: (2021)

Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus
por: Shibata, Ryo, et al.
Publicado: (2022)

Correction to: Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus
por: Shibata, Ryo, et al.
Publicado: (2022)

FcRγ-dependent immune activation initiates astrogliosis during the asymptomatic phase of Sandhoff disease model mice
por: Ogawa, Yasuhiro, et al.
Publicado: (2017)

Impaired Neural Differentiation of Induced Pluripotent Stem Cells Generated from a Mouse Model of Sandhoff Disease
por: Ogawa, Yasuhiro, et al.
Publicado: (2013)

L-Carnitine Supplementation Improves Self-Rating Depression Scale Scores in Uremic Male Patients Undergoing Hemodialysis
por: Tashiro, Kyoko, et al.
Publicado: (2017)

Fabry disease
por: Germain, Dominique P
Publicado: (2010)

Late onset variants in Fabry disease: Results in high risk population screenings in Argentina
por: Serebrinsky, G., et al.
Publicado: (2015)

Serum Levels of Growth Differentiation Factor 11 Are Independently Associated with Low Hemoglobin Values in Hemodialysis Patients
por: Yamagishi, Sho-ichi, et al.
Publicado: (2016)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Fabry Disease on Peritoneal Dialysis with Cardiac Involvement
por: Koga-Kobori, Sayako, et al.
Publicado: (2020)

Clinical utility of urinary mulberry bodies/cells testing in the diagnosis of Fabry disease
por: Nakamura, Katsuya, et al.
Publicado: (2023)

Fabry Disease and Early Stroke
por: Feldt-Rasmussen, U.
Publicado: (2011)

Endoscopic images in Fabry disease
por: Kouvaras, Stergios N.
Publicado: (2012)

Motor involvement in Fabry disease
por: Cocozza, Sirio, et al.
Publicado: (2017)

Hot topics in Fabry disease
por: Cairns, Tereza, et al.
Publicado: (2018)

Fabry disease and incidence of cancer
por: Bird, Sarah, et al.
Publicado: (2017)

Developments in the treatment of Fabry disease
por: van der Veen, Sanne J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8dlu6osdtv14v6tovv13euckuq